MENU
+Compare
ACAD
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$19.95
Change
-$0.34 (-1.68%)
Capitalization
3.32B

ACAD ACADIA Pharmaceuticals Forecast, Technical & Fundamental Analysis

a developer of pharmaceuticals drugs for treatment of central nervous system disorders

Industry Biotechnology
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ACAD with price predictions
Feb 20, 2025

ACAD in downward trend: price expected to drop as it breaks its higher Bollinger Band on February 13, 2025

ACAD broke above its upper Bollinger Band on February 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In of the 41 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on February 10, 2025. You may want to consider a long position or call options on ACAD as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ACAD just turned positive on February 13, 2025. Looking at past instances where ACAD's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

ACAD moved above its 50-day moving average on January 15, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACAD advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 200 cases where ACAD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ACAD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.747) is normal, around the industry mean (12.644). P/E Ratio (25.564) is within average values for comparable stocks, (84.748). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.591). ACAD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (3.557) is also within normal values, averaging (254.739).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ACAD is expected to report earnings to rise 9.40% to 21 cents per share on March 03

ACADIA Pharmaceuticals ACAD Stock Earnings Reports
Q4'24
Est.
$0.22
Q3'24
Beat
by $0.06
Q2'24
Beat
by $0.02
Q1'24
Beat
by $0.05
Q4'23
Missed
by $0.01
The last earnings report on November 06 showed earnings per share of 20 cents, beating the estimate of 14 cents. With 2.00M shares outstanding, the current market capitalization sits at 3.32B.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals drugs for treatment of central nervous system disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12830 El Camino Real
Phone
+1 858 558-2871
Employees
598
Web
https://www.acadia.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NWHFX15.53N/A
N/A
Nationwide Bailard Cogntv Val M
RFNEX85.14N/A
N/A
American Funds Fundamental Invs R4
CCGIX25.44N/A
N/A
Baird Chautauqua Global Growth Instl
CCWIX20.82N/A
N/A
Baird Chautauqua International Gr Instl
VVIPX15.26N/A
N/A
Voya VACS Index S

ACAD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with VRTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+3.15%
VRTX - ACAD
46%
Loosely correlated
+1.82%
CCCC - ACAD
43%
Loosely correlated
-0.66%
RGNX - ACAD
43%
Loosely correlated
-1.34%
XNCR - ACAD
40%
Loosely correlated
-2.53%
MGTX - ACAD
40%
Loosely correlated
-0.87%
More